Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.
Bottorff
M
M
D016907:Adverse Drug Reaction Reporting Systems; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D004347:Drug Interactions; D006801:Humans; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors*; D019821:Simvastatin / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D002121:Calcium Channel Blockers; D065607:Cytochrome P-450 Enzyme Inhibitors; D019821:Simvastatin; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A